Expect Limited Use of IV Brexanolone (Zulresso) for Postpartum Depression
Intravenous brexanolone (Zulresso, zul-REH-soh) will make a splash as the first FDA-approved treatment for postpartum depression.
Brexanolone has a unique mechanism...it mimics the hormone allopregnanolone, which interacts with GABA receptors. This hormone abruptly dips around childbirth...possibly leading to major depression.
Brexanolone is given as a single 60-hour infusion. It starts to improve depression symptoms 24 to 48 hours after starting the infusion. In comparison, SSRIs take at least 1 to 2 weeks to start working.
Get unlimited access through an Enterprise license
Hospital Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 300+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Not sold to individuals